Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00599716 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome
A Phase 3 study of Dry Eye Disease, sponsored by Lantibio.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 10
- Study locations
NCT00599716: Completed Phase 3 study of Dry Eye Disease, sponsored by Lantibio.
NCT00599716 is a Phase 3 study of Dry Eye Disease that has completed, run by Lantibio. The registered enrollment target is 300 participants, above the 246-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (22% higher). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00599716, a Phase 3 study of Dry Eye Disease, has completed, sponsored by Lantibio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 10
- Study locations
Study Summary
The study is designed to assess the safety and efficacy of Vismed®, a special eye drop containing sodium hyaluronate, in the treatment of dry eye syndrome. Vismed® is being compared to another eye drop, identical in composition except that it does not contain the active ingredient, sodium hyaluronate. This eye drop is designed as the "vehicle." Some subjects are to receive Vismed® treatment, while others are to receive the vehicle; the assignment of subjects to receive either Vismed or vehicle is to be random. The two-week treatment phase is followed by a one week follow-up period to evaluate safety of Vismed®.
Conditions Studied
Interventions
- DRUG vehicle
- DRUG sodium hyaluronate
Study Locations (10)
Florida
- Florida Eye Microsurgical Institute - Boynton Beach
- Center for Excellence in Eye Care - Miami
- East Florida Eye Institutue - Stuart
- Abrams Eye Center - Stuart
- International Eye Center - Tampa
Indiana
- American Eye Institute - New Albany
Missouri
- Comprehensive Eye Care - Washington
North Carolina
- Charlotte Eye, Ear, Nose and Throat - Charlotte
Pennsylvania
- Ophthalmic Research & Clinical Studies - Moon Twp
Tennessee
- Chattanooga Eye Institute - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
What the finished NCT00599716 record still lists
NCT00599716 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 246-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (22% higher).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which vehicle is the first listed.
NCT00599716 lists 10 locations in 6 states (Florida, Indiana, Missouri).
Frequently Asked Questions
What is clinical trial NCT00599716 about?
NCT00599716 is a clinical study titled "Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome". The study is designed to assess the safety and efficacy of Vismed®, a special eye drop containing sodium hyaluronate, in the treatment of dry eye syndrome. Vismed® is being compared to another eye drop, identical in composition except that it does not contain the active ingredient, sodium hyaluronat...
What is the current status of trial NCT00599716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2006-12. Estimated completion is 2008-05.
What conditions does trial NCT00599716 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT00599716?
The interventions under investigation include: vehicle (DRUG), sodium hyaluronate (DRUG).
Who is sponsoring clinical trial NCT00599716?
This trial is sponsored by Lantibio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00599716 being conducted?
This trial has 10 study locations across Florida, Indiana, Missouri, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00599716's enrollment target sits among peer trials
300 11th of 33 higher than 23 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
COMPLETED · Phase 3
-
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
COMPLETED · Phase 3
-
A Study Designed to Evaluate Tear Production
COMPLETED · Phase 3
-
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia